This new identity signifies a global footprint and an extended range of services, and symbolises the commitment to ensuring a consistent and high-quality experience for customers.
With 700 employees and five operating sites across the US and the UK, Quotient is focused on delivering a portfolio of innovative services encompassing formulation development, clinical trial and commercial manufacturing, and clinical pharmacology.
Quotient’s Translational Pharmaceutics platform integrates formulation development, real-time adaptive GMP manufacturing and clinical research, transforming the traditional industry approach of outsourcing to independent contract development and manufacturing organisations (CDMOs) and contract research organisations (CROs).
Translational Pharmaceutics is proven to accelerate development timelines and reduce overall costs.
“We are excited about the future of Quotient Sciences,” said Mark Egerton, CEO at Quotient Sciences.
“By integrating services typically found in disparate CDMOs and CROs, we break down barriers and support our customers to improve R&D productivity and accelerate the delivery of new medicines to patients around the world. We have a 30-year track record of service to a global customer base, including large multinational pharmaceutical companies to smaller virtual biotech organisations.”
